NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

NCT04920539

CompletedPhase 1

Sponsor: Yale University

Conditions: HIV Infections, Healthy

Interventions: Active Delta-9-THC

Countries: United States

In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria (HIV-infected group):

* HIV-positive
* Good medication adherence
* Negative urine toxicology for drugs of abuse (including cannabis)
* Good mental and physical health (other than HIV) as determined by history, psychiatric interview, collateral information, physical and laboratory examinations, ECG, and vital signs.

Inclusion Criteria (HIV-uninfected group):

* HIV-negative
* Negative urine toxicology for drugs of abuse (including cannabis)
* Good mental and physical health as determined by history, psychiatric interview, collateral information, physical and laboratory examinations, ECG, and vital signs.

Exclusion Criteria (common to both groups):

* Major medical conditions, e.g., myocardial infarction, hypertension, etc.
* Positive pregnancy test and lactation;
* Weight greater than 166 kg (365 lbs)

Locations (1)

West Haven, Connecticut, United States